Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD8586 Combination Therapy in Diffuse Large B-cell Lymphoma
NCT07059650Phase 2Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Oct 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of birelentinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Aug 2025; status: recruiting.
02
Drugs
birelentinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07059650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059650.